51
|
Han MZ, Wang S, Zhao WB, Ni SL, Yang N, Kong Y, Huang B, Chen AJ, Li XG, Wang J, Wang DH. Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma. EBioMedicine 2019; 43:159-170. [PMID: 30987862 PMCID: PMC6557785 DOI: 10.1016/j.ebiom.2019.04.002] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Revised: 03/13/2019] [Accepted: 04/01/2019] [Indexed: 11/05/2022] Open
Abstract
Background Dysregulation of immune checkpoint molecules leads to immune evasion in human tumours but has become a viable target for tumour therapy. Here, we examined expression of Herpes virus entry mediator (HVEM), an immune checkpoint molecule, in human glioblastoma (GBM) to assess its potential as a molecular target for treatment. Methods Molecular and clinical data from publicly available genomic databases containing WHO grade II-IV human glioma cases (n = 1866) were analyzed. Immunohistochemistry was applied to assess HVEM protein levels in primary tumour sections. Statistical analysis was performed using Matlab and R language. Findings HVEM was found to be elevated in aggressive gliomas, particularly in the mesenchymal and isocitrate dehydrogenase (IDH) wild-type molecular subtypes of GBM. HVEMhigh tumours tended to be associated with amplification of EGFR and loss of PTEN, while HVEMlow tumours harbored mutations in IDH1 (93%). HVEM exhibited potential as a prognostic marker based on Cox regression and nomogram models. HVEM displayed intra-tumour heterogeneity and was more highly expressed in peri-necrotic and microvascular regions. Gene ontology and pathway analysis revealed enrichment of HVEM in multiple immune regulatory processes, such as suppression of T cell mediated immunity in GBM. Finally, in cell lineage analysis, HVEM was found to be tightly associated with several infiltrating immune and stromal cell types which localized to the tumour microenvironment. Interpretation Our data highlights the importance of HVEM in the development of GBM and as a potential molecular target in combination with current immune checkpoint blockades for treatment of GBM.
Collapse
Affiliation(s)
- Ming-Zhi Han
- Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, 107# Wenhua Xi Road, Jinan 250012, China; K.G. Jebsen Brain Tumour Research Center, Department of Biomedicine, University of Bergen, Jonas Lies vei 91, 5009 Bergen, Norway
| | - Shuai Wang
- Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, 107# Wenhua Xi Road, Jinan 250012, China
| | - Wen-Bo Zhao
- Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, 107# Wenhua Xi Road, Jinan 250012, China
| | - Shi-Lei Ni
- Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, 107# Wenhua Xi Road, Jinan 250012, China
| | - Ning Yang
- Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, 107# Wenhua Xi Road, Jinan 250012, China
| | - Yang Kong
- Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, 107# Wenhua Xi Road, Jinan 250012, China
| | - Bin Huang
- Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, 107# Wenhua Xi Road, Jinan 250012, China
| | - An-Jing Chen
- Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, 107# Wenhua Xi Road, Jinan 250012, China
| | - Xin-Gang Li
- Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, 107# Wenhua Xi Road, Jinan 250012, China
| | - Jian Wang
- Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, 107# Wenhua Xi Road, Jinan 250012, China; K.G. Jebsen Brain Tumour Research Center, Department of Biomedicine, University of Bergen, Jonas Lies vei 91, 5009 Bergen, Norway
| | - Dong-Hai Wang
- Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, 107# Wenhua Xi Road, Jinan 250012, China.
| |
Collapse
|
52
|
Andreou C, Oseledchyk A, Nicolson F, Berisha N, Pal S, Kircher MF. Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting. J Vis Exp 2019. [PMID: 30958459 DOI: 10.3791/58389] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Ovarian cancer represents the deadliest gynecologic malignancy. Most patients present at an advanced stage (FIGO stage III or IV), when local metastatic spread has already occurred. However, ovarian cancer has a unique pattern of metastatic spread, in that tumor implants are initially contained within the peritoneal cavity. This feature could enable, in principle, the complete resection of tumor implants with curative intent. Many of these metastatic lesions are microscopic, making them hard to identify and treat. Neutralizing such micrometastases is believed to be a major goal towards eliminating tumor recurrence and achieving long-term survival. Raman imaging with surface enhanced resonance Raman scattering nanoprobes can be used to delineate microscopic tumors with high sensitivity, due to their bright and bioorthogonal spectral signatures. Here, we describe the synthesis of two 'flavors' of such nanoprobes: an antibody-functionalized one that targets the folate receptor - overexpressed in many ovarian cancers - and a non-targeted control nanoprobe, with distinct spectra. The nanoprobes are co-administered intraperitoneally to mouse models of metastatic human ovarian adenocarcinoma. All animal studies were approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center. The peritoneal cavity of the animals is surgically exposed, washed, and scanned with a Raman microphotospectrometer. Subsequently, the Raman signatures of the two nanoprobes are decoupled using a Classical Least Squares fitting algorithm, and their respective scores divided to provide a ratiometric signal of folate-targeted over untargeted probes. In this way, microscopic metastases are visualized with high specificity. The main benefit of this approach is that the local application into the peritoneal cavity - which can be done conveniently during the surgical procedure - can tag tumors without subjecting the patient to systemic nanoparticle exposure. False positive signals stemming from non-specific binding of the nanoprobes onto visceral surfaces can be eliminated by following a ratiometric approach where targeted and non-targeted nanoprobes with distinct Raman signatures are applied as a mixture. The procedure is currently still limited by the lack of a commercial wide-field Raman imaging camera system, which once available will allow for the application of this technique in the operating theater.
Collapse
Affiliation(s)
| | | | - Fay Nicolson
- Department of Radiology, Memorial Sloan Kettering Cancer Center
| | - Naxhije Berisha
- Department of Radiology, Memorial Sloan Kettering Cancer Center; Department of Chemistry, The Graduate Center of the City University of New York
| | - Suchetan Pal
- Department of Radiology, Memorial Sloan Kettering Cancer Center
| | - Moritz F Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center; Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center; Gerstner Sloan Kettering Graduate School of Biomedical Sciences; Department of Radiology, Weill Cornell Medical College of Cornell University; Dana-Farber Cancer Institute and Harvard Medical Center;
| |
Collapse
|
53
|
Umlauf BJ, Shusta EV. Exploiting BBB disruption for the delivery of nanocarriers to the diseased CNS. Curr Opin Biotechnol 2019; 60:146-152. [PMID: 30849699 DOI: 10.1016/j.copbio.2019.01.013] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Revised: 12/20/2018] [Accepted: 01/21/2019] [Indexed: 12/16/2022]
Affiliation(s)
- Benjamin J Umlauf
- Department of Chemical and Biological Engineering, University of Wisconsin-Madison, United States
| | - Eric V Shusta
- Department of Chemical and Biological Engineering, University of Wisconsin-Madison, United States.
| |
Collapse
|
54
|
Harmsen S, Rogalla S, Huang R, Spaliviero M, Neuschmelting V, Hayakawa Y, Lee Y, Tailor Y, Toledo-Crow R, Kang JW, Samii JM, Karabeber H, Davis RM, White JR, van de Rijn M, Gambhir SS, Contag CH, Wang TC, Kircher MF. Detection of Premalignant Gastrointestinal Lesions Using Surface-Enhanced Resonance Raman Scattering-Nanoparticle Endoscopy. ACS NANO 2019; 13:1354-1364. [PMID: 30624916 PMCID: PMC6428194 DOI: 10.1021/acsnano.8b06808] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Cancers of the gastrointestinal (GI) tract are among the most frequent and most lethal cancers worldwide. An important reason for this high mortality is that early disease is typically asymptomatic, and patients often present with advanced, incurable disease. Even in high-risk patients who routinely undergo endoscopic screening, lesions can be missed due to their small size or subtle appearance. Thus, current imaging approaches lack the sensitivity and specificity to accurately detect incipient GI tract cancers. Here we report our finding that a single dose of a high-sensitivity surface-enhanced resonance Raman scattering nanoparticle (SERRS-NP) enables reliable detection of precancerous GI lesions in animal models that closely mimic disease development in humans. Some of these animal models have not been used previously to evaluate imaging probes for early cancer detection. The studies were performed using a commercial Raman imaging system, a newly developed mouse Raman endoscope, and finally a clinically applicable Raman endoscope for larger animal studies. We show that this SERRS-NP-based approach enables robust detection of small, premalignant lesions in animal models that faithfully recapitulate human esophageal, gastric, and colorectal tumorigenesis. This method holds promise for much earlier detection of GI cancers than currently possible and could lead therefore to marked reduction of morbidity and mortality of these tumor types.
Collapse
Affiliation(s)
- Stefan Harmsen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
- Department of Pediatrics, Stanford University, Stanford, California 94305, United States
- Department of Radiology, Stanford University, Stanford, California 94305, United States
| | - Stephan Rogalla
- Department of Pediatrics, Stanford University, Stanford, California 94305, United States
- Department of Radiology, Stanford University, Stanford, California 94305, United States
| | - Ruimin Huang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
| | - Massimiliano Spaliviero
- Urology Service, Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
| | - Volker Neuschmelting
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
- Department of Neurosurgery, University Hospital Cologne, Cologne 50937, Germany
| | - Yoku Hayakawa
- Department of Medicine, Columbia University, New York, New York 10032, United States
| | - Yoomi Lee
- Department of Medicine, Columbia University, New York, New York 10032, United States
| | - Yagnesh Tailor
- Department of Medicine, Columbia University, New York, New York 10032, United States
| | - Ricardo Toledo-Crow
- Research Engineering Lab, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
| | - Jeon Woong Kang
- Laser Biomedical Research Center, G. R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Jason M. Samii
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
| | - Hazem Karabeber
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
| | - Ryan M. Davis
- Department of Radiology, Stanford University, Stanford, California 94305, United States
| | - Julie R. White
- Tri-Institutional Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College, New York, New York 10065, United States
- Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
| | - Matt van de Rijn
- Department of Pathology, Stanford University, Stanford, California 94305, United States
| | - Sanjiv S. Gambhir
- Department of Radiology, Stanford University, Stanford, California 94305, United States
- Department of Bioengineering, Department of Materials Science & Engineering, Molecular Imaging Program at Stanford, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, California 94305, United States
| | - Christopher H. Contag
- Department of Pediatrics, Stanford University, Stanford, California 94305, United States
- Department of Microbiology and Immunology, Stanford University, Stanford, California 94305, United States
- Institute of Quantitative Health Science and Engineering, Department of Biomedical Engineering, and Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan 48824, United States
- Corresponding Authors., .,
| | - Timothy C. Wang
- Department of Medicine, Columbia University, New York, New York 10032, United States
- Corresponding Authors., .,
| | - Moritz F. Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
- Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, United States
- Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, United States
- Department of Imaging, Dana-Farber Cancer Institute & Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02215, United States
- Corresponding Authors., .,
| |
Collapse
|
55
|
Sloan-Dennison S, Schultz ZD. Label-free plasmonic nanostar probes to illuminate in vitro membrane receptor recognition. Chem Sci 2019; 10:1807-1815. [PMID: 30842849 PMCID: PMC6369441 DOI: 10.1039/c8sc05035j] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Accepted: 11/30/2018] [Indexed: 01/24/2023] Open
Abstract
Protein-ligand recognition is a key activity where chemical signals are communicated to cells to activate various biochemical pathways, which are important for understanding membrane signaling and drug interactions. Gold nanostars are highly attractive for biological applications due to their readily modified surface chemistry, facile synthesis and optical properties. The increase in electromagnetic field at their branches increases the surface enhanced Raman scattering (SERS) making them ideal candidates as label free in vitro probes that can be used to detect a variety of cellular activities. However, the use of particles in vitro is complicated by the adsorption of proteins, which forms the protein corona. In this paper we demonstrate gold nanostars as label free in vitro probes to study the interaction between αvβ3 integrin and RGD. Nanostars functionalized with cyclic-RDGFC reduced the formation of the protein corona, due to its zwitterionic nature, indicating a small peptide approach to minimizing protein absorption. Additionally, the functionalized nanostars evince a SERS response from their interaction with αvβ3 integrin representative of the amino acids present at the binding site which is also retained in a complex biological matrix. The nanostars were used in vitro to selectively detect αvβ3 integrin on the membrane of human metastatic colon cancer cells. By exploiting the intense SERS and tunable plasmon resonance properties of gold nanostars functionalized with cyclic RGDFC, we have demonstrated a label free approach to investigate the chemical interactions associated with protein-ligand binding from both purified proteins and membrane bound receptors in cells.
Collapse
Affiliation(s)
- Sian Sloan-Dennison
- Department of Chemistry and Biochemistry , The Ohio State University , Columbus , OH 43210 , USA .
| | - Zachary D Schultz
- Department of Chemistry and Biochemistry , The Ohio State University , Columbus , OH 43210 , USA .
| |
Collapse
|
56
|
Delineating the tumor margin with intraoperative surface-enhanced Raman spectroscopy. Anal Bioanal Chem 2019; 411:3993-4006. [DOI: 10.1007/s00216-019-01577-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2018] [Revised: 12/21/2018] [Accepted: 01/04/2019] [Indexed: 10/27/2022]
|
57
|
Full-Scale Label-Free Surface-Enhanced Raman Scattering Analysis of Mouse Brain Using a Black Phosphorus-Based Two-Dimensional Nanoprobe. APPLIED SCIENCES-BASEL 2019. [DOI: 10.3390/app9030398] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The brain takes the vital role in human physiological and psychological activities. The precise understanding of the structure of the brain can supply the material basis for the psychological behavior and cognitive ability of human beings. In this study, a fast molecular fingerprint analysis of mouse brain tissue was performed using surface-enhanced Raman scattering (SERS) spectroscopy. A nanohybrid consisting of flake-like black phosphorus (BP) and Au nanoparticles (BP-AuNSs) served as the novel SERS substrate for the spectral analysis of brain tissue. BP-AuNSs exhibited outstanding SERS activity compared to the traditional citrate-stabilized Au nanoparticles, which could be largely ascribed to the plentiful hot spots formed in the BP nanosheet. Rapid, full-scale and label-free SERS imaging of mouse brain tissue was then realized with a scanning speed of 56 ms per pixel. Fine textures and clear contour were observed in the SERS images of brain tissue, which could be well in accordance with the classical histological analysis; however, it could avoid the disadvantages in the processing procedure of tissue section. Additionally, the SERS spectra illustrated plentiful biochemical fingerprint of brain tissue, which indicated the molecular composition of various encephalic regions. The SERS difference spectrum of the left versus right hemisphere revealed the biochemical difference between the two hemispheres, which helped to uncover the psychological and cognitive models of the left and right hemispheres.
Collapse
|
58
|
Tang W, Fan W, Lau J, Deng L, Shen Z, Chen X. Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem Soc Rev 2019; 48:2967-3014. [DOI: 10.1039/c8cs00805a] [Citation(s) in RCA: 242] [Impact Index Per Article: 48.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The advancements, perspectives, and challenges in blood–brain-barrier (BBB)-crossing nanotechnology for effective brain tumor delivery and highly efficient brain cancer theranostics.
Collapse
Affiliation(s)
- Wei Tang
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN)
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- National Institutes of Health (NIH)
- Bethesda
- USA
| | - Wenpei Fan
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN)
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- National Institutes of Health (NIH)
- Bethesda
- USA
| | - Joseph Lau
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN)
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- National Institutes of Health (NIH)
- Bethesda
- USA
| | - Liming Deng
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN)
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- National Institutes of Health (NIH)
- Bethesda
- USA
| | - Zheyu Shen
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN)
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- National Institutes of Health (NIH)
- Bethesda
- USA
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN)
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- National Institutes of Health (NIH)
- Bethesda
- USA
| |
Collapse
|
59
|
Auner GW, Koya SK, Huang C, Broadbent B, Trexler M, Auner Z, Elias A, Mehne KC, Brusatori MA. Applications of Raman spectroscopy in cancer diagnosis. Cancer Metastasis Rev 2018; 37:691-717. [PMID: 30569241 PMCID: PMC6514064 DOI: 10.1007/s10555-018-9770-9] [Citation(s) in RCA: 178] [Impact Index Per Article: 29.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Novel approaches toward understanding the evolution of disease can lead to the discovery of biomarkers that will enable better management of disease progression and improve prognostic evaluation. Raman spectroscopy is a promising investigative and diagnostic tool that can assist in uncovering the molecular basis of disease and provide objective, quantifiable molecular information for diagnosis and treatment evaluation. This technique probes molecular vibrations/rotations associated with chemical bonds in a sample to obtain information on molecular structure, composition, and intermolecular interactions. Raman scattering occurs when light interacts with a molecular vibration/rotation and a change in polarizability takes place during molecular motion. This results in light being scattered at an optical frequency shifted (up or down) from the incident light. By monitoring the intensity profile of the inelastically scattered light as a function of frequency, the unique spectroscopic fingerprint of a tissue sample is obtained. Since each sample has a unique composition, the spectroscopic profile arising from Raman-active functional groups of nucleic acids, proteins, lipids, and carbohydrates allows for the evaluation, characterization, and discrimination of tissue type. This review provides an overview of the theory of Raman spectroscopy, instrumentation used for measurement, and variation of Raman spectroscopic techniques for clinical applications in cancer, including detection of brain, ovarian, breast, prostate, and pancreatic cancers and circulating tumor cells.
Collapse
Affiliation(s)
- Gregory W Auner
- Michael and Marian Ilitch Department of Surgery, School of Medicine, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA.
- Department of Biomedical Engineering, College of Engineering, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA.
- Smart Sensors and Integrated Microsystems Program, Wayne State University, Detroit, MI, 48202, USA.
- Henry Ford Health Systems, Detroit Institute of Ophthalmology, Grosse Pointe Park, MI, 48230, USA.
| | - S Kiran Koya
- Michael and Marian Ilitch Department of Surgery, School of Medicine, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA
- Department of Biomedical Engineering, College of Engineering, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA
- Smart Sensors and Integrated Microsystems Program, Wayne State University, Detroit, MI, 48202, USA
| | - Changhe Huang
- Michael and Marian Ilitch Department of Surgery, School of Medicine, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA
- Department of Biomedical Engineering, College of Engineering, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA
- Smart Sensors and Integrated Microsystems Program, Wayne State University, Detroit, MI, 48202, USA
| | - Brandy Broadbent
- Department of Biomedical Engineering, College of Engineering, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA
- Smart Sensors and Integrated Microsystems Program, Wayne State University, Detroit, MI, 48202, USA
| | - Micaela Trexler
- Department of Biomedical Engineering, College of Engineering, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA
- Smart Sensors and Integrated Microsystems Program, Wayne State University, Detroit, MI, 48202, USA
| | - Zachary Auner
- Smart Sensors and Integrated Microsystems Program, Wayne State University, Detroit, MI, 48202, USA
- Department of Physics & Astronomy, Wayne State University, Detroit, MI, 48202, USA
| | - Angela Elias
- Department of Biomedical Engineering, College of Engineering, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA
- Smart Sensors and Integrated Microsystems Program, Wayne State University, Detroit, MI, 48202, USA
| | - Katlyn Curtin Mehne
- Department of Biomedical Engineering, College of Engineering, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA
- Smart Sensors and Integrated Microsystems Program, Wayne State University, Detroit, MI, 48202, USA
| | - Michelle A Brusatori
- Michael and Marian Ilitch Department of Surgery, School of Medicine, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA
- Department of Biomedical Engineering, College of Engineering, Wayne State University, 5050 Anthony Wayne Drive, Detroit, MI, 48202, USA
- Smart Sensors and Integrated Microsystems Program, Wayne State University, Detroit, MI, 48202, USA
| |
Collapse
|
60
|
Del Bonis-O’Donnell JT, Chio L, Dorlhiac GF, McFarlane IR, Landry MP. Advances in Nanomaterials for Brain Microscopy. NANO RESEARCH 2018; 11:5144-5172. [PMID: 31105899 PMCID: PMC6516768 DOI: 10.1007/s12274-018-2145-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Revised: 07/05/2018] [Accepted: 07/08/2018] [Indexed: 05/19/2023]
Abstract
Microscopic imaging of the brain continues to reveal details of its structure, connectivity, and function. To further improve our understanding of the emergent properties and functions of neural circuits, new methods are necessary to directly visualize the relationship between brain structure, neuron activity, and neurochemistry. Advances in engineering the chemical and optical properties of nanomaterials concurrent with developments in deep-tissue microscopy hold tremendous promise for overcoming the current challenges associated with in vivo brain imaging, particularly for imaging the brain through optically-dense brain tissue, skull, and scalp. To this end, developments in nanomaterials offer much promise toward implementing tunable chemical functionality for neurochemical targeting and sensing, and fluorescence stability for long-term imaging. In this review, we summarize current brain microscopy methods and describe the diverse classes of nanomaterials recently leveraged as contrast agents and functional probes for microscopic optical imaging of the brain.
Collapse
Affiliation(s)
| | - Linda Chio
- Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA 94720
| | - Gabriel F Dorlhiac
- Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA 94720
| | - Ian R McFarlane
- Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA 94720
| | - Markita P Landry
- Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA 94720
- Innovative Genomics Institute (IGI), Berkeley, CA 94720
- California Institute for Quantitative Biosciences, QB3, University of California, Berkeley, CA 94720
- Chan-Zuckerberg Biohub, San Francisco, CA 94158
| |
Collapse
|
61
|
Advances in transformable drug delivery systems. Biomaterials 2018; 178:546-558. [DOI: 10.1016/j.biomaterials.2018.03.056] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Revised: 03/21/2018] [Accepted: 03/31/2018] [Indexed: 12/14/2022]
|
62
|
Bhamidipati M, Cho HY, Lee KB, Fabris L. SERS-Based Quantification of Biomarker Expression at the Single Cell Level Enabled by Gold Nanostars and Truncated Aptamers. Bioconjug Chem 2018; 29:2970-2981. [PMID: 30110153 DOI: 10.1021/acs.bioconjchem.8b00397] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Surface-enhanced Raman spectroscopy (SERS)-based biosensors have been used increasingly over the past few years for cancer detection and diagnosis. SERS-based imaging offers excellent sensitivity and has advantages over other detection techniques such as fluorescence. In this study, we developed a novel biosensor to detect the cancer biomarker epithelial cell adhesion molecule (EpCAM) and quantify its expression at the single cell level. EpCAM is one of the most commonly expressed markers on a variety of cancer cells; importantly it has been suggested that reduction of its expression levels could be associated with the epithelial to mesenchymal transition (EMT) and thus to the onset of metastasis. Therefore, monitoring variations in expression levels of this membrane biomarker would improve our ability to monitor cancer progression. The described substrate-based biosensor was developed employing gold nanostars functionalized with EpCAM aptamer molecules and was able to quantify subnanomolar concentrations of EpCAM protein in solution. Importantly, we demonstrated its use to quantify EpCAM expression on the surface of two cancer cells, MCF-7 and PC-3. We also compared the binding efficiency of two EpCAM DNA aptamers of different lengths and observed a substantial improvement in the sensitivity of detection by employing the shorter aptamer sequence, probably due to the reduced number of conformations possible at room temperature with the truncated oligonucleotide. Detailed characterization of the substrates was carried out using both SERS maps and atomic force microscopy. These substrate-based diagnostic devices promise to be relevant for monitoring phenotype evolutions in cancer cells, blood, and other bodily fluids, thus improving our ability to follow in real time disease onset and progression.
Collapse
Affiliation(s)
- Manjari Bhamidipati
- Department of Biomedical Engineering , Rutgers University , 599 Taylor Road , Piscataway , New Jersey 08854 , United States
| | - Hyeon-Yeol Cho
- Department of Chemistry and Chemical Biology , Rutgers University , 610 Taylor Road , Piscataway , New Jersey 08854 , United States
| | - Ki-Bum Lee
- Department of Chemistry and Chemical Biology , Rutgers University , 610 Taylor Road , Piscataway , New Jersey 08854 , United States.,College of Pharmacy , Kyung Hee University , 26 Kyunghee-daero , Seoul 02447 , Republic of Korea
| | - Laura Fabris
- Department of Materials Science and Engineering , Rutgers University , 607 Taylor Road , Piscataway , New Jersey 08854 , United States
| |
Collapse
|
63
|
Lane LA, Xue R, Nie S. Emergence of two near-infrared windows for in vivo and intraoperative SERS. Curr Opin Chem Biol 2018; 45:95-103. [PMID: 29631122 PMCID: PMC6076872 DOI: 10.1016/j.cbpa.2018.03.015] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Revised: 03/25/2018] [Accepted: 03/27/2018] [Indexed: 12/18/2022]
Abstract
Two clear windows in the near-infrared (NIR) spectrum are of considerable current interest for in vivo molecular imaging and spectroscopic detection. The main rationale is that near-infrared light can penetrate biological tissues such as skin and blood more efficiently than visible light because these tissues scatter and absorb less light at longer wavelengths. The first clear window, defined as light wavelengths between 650nm and 950nm, has been shown to be far superior for in vivo and intraoperative optical imaging than visible light. The second clear window, operating in the wavelength range of 1000-1700nm, has been reported to further improve detection sensitivity, spatial resolution, and tissue penetration because tissue photon scattering and background interference are further reduced at longer wavelengths. Here we discuss recent advances in developing biocompatible plasmonic nanoparticles for in vivo and intraoperative surface-enhanced Raman scattering (SERS) in both the first and second NIR windows. In particular, a new class of 'broad-band' plasmonic nanostructures is well suited for surface Raman enhancement across a broad range of wavelengths allowing a direct comparison of detection sensitivity and tissue penetration between the two NIR window. Also, optimized and encoded SERS nanoparticles are generally nontoxic and are much brighter than near-infrared quantum dots (QDs), raising new possibilities for ultrasensitive detection of microscopic tumors and image-guided precision surgery.
Collapse
Affiliation(s)
- Lucas A Lane
- Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing University, Nanjing, China.
| | - Ruiyang Xue
- Departments of Bioengineering, Chemistry, Electrical and Computer Engineering, and Materials Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Shuming Nie
- Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing University, Nanjing, China; Departments of Bioengineering, Chemistry, Electrical and Computer Engineering, and Materials Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
| |
Collapse
|
64
|
Zhang P, Cui Y, Anderson CF, Zhang C, Li Y, Wang R, Cui H. Peptide-based nanoprobes for molecular imaging and disease diagnostics. Chem Soc Rev 2018; 47:3490-3529. [PMID: 29497722 DOI: 10.1039/c7cs00793k] [Citation(s) in RCA: 97] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Pathological changes in a diseased site are often accompanied by abnormal activities of various biomolecules in and around the involved cells. Identifying the location and expression levels of these biomolecules could enable early-stage diagnosis of the related disease, the design of an appropriate treatment strategy, and the accurate assessment of the treatment outcomes. Over the past two decades, a great diversity of peptide-based nanoprobes (PBNs) have been developed, aiming to improve the in vitro and in vivo performances of water-soluble molecular probes through engineering of their primary chemical structures as well as the physicochemical properties of their resultant assemblies. In this review, we introduce strategies and approaches adopted for the identification of functional peptides in the context of molecular imaging and disease diagnostics, and then focus our discussion on the design and construction of PBNs capable of navigating through physiological barriers for targeted delivery and improved specificity and sensitivity in recognizing target biomolecules. We highlight the biological and structural roles that low-molecular-weight peptides play in PBN design and provide our perspectives on the future development of PBNs for clinical translation.
Collapse
Affiliation(s)
- Pengcheng Zhang
- State Key Laboratory of Drug Research & Center for Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China.
| | | | | | | | | | | | | |
Collapse
|
65
|
Neuschmelting V, Harmsen S, Beziere N, Lockau H, Hsu HT, Huang R, Razansky D, Ntziachristos V, Kircher MF. Dual-Modality Surface-Enhanced Resonance Raman Scattering and Multispectral Optoacoustic Tomography Nanoparticle Approach for Brain Tumor Delineation. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2018; 14:e1800740. [PMID: 29726109 PMCID: PMC6541212 DOI: 10.1002/smll.201800740] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Revised: 03/22/2018] [Indexed: 06/08/2023]
Abstract
Difficulty in visualizing glioma margins intraoperatively remains a major issue in the achievement of gross total tumor resection and, thus, better clinical outcome of glioblastoma (GBM) patients. Here, the potential of a new combined optical + optoacoustic imaging method for intraoperative brain tumor delineation is investigated. A strategy using a newly developed gold nanostar synthesis method, Raman reporter chemistry, and silication method to produce dual-modality contrast agents for combined surface-enhanced resonance Raman scattering (SERRS) and multispectral optoacoustic tomography (MSOT) imaging is devised. Following intravenous injection of the SERRS-MSOT-nanostars in brain tumor bearing mice, sequential MSOT imaging is performed in vivo and followed by Raman imaging. MSOT is able to accurately depict GBMs three-dimensionally with high specificity. The MSOT signal is found to correlate well with the SERRS images. Because SERRS enables uniquely sensitive high-resolution surface detection, it could represent an ideal complementary imaging modality to MSOT, which enables real-time, deep tissue imaging in 3D. This dual-modality SERRS-MSOT-nanostar contrast agent reported here is shown to enable high precision depiction of the extent of infiltrating GBMs by Raman- and MSOT imaging in a clinically relevant murine GBM model and could pave new ways for improved image-guided resection of brain tumors.
Collapse
Affiliation(s)
- Volker Neuschmelting
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
- Department of Neurosurgery, University Hospital Cologne, Cologne, Germany
- Institute for Biological and Medical Imaging, Technical University of Munich and Helmholtz Center, Munich, Germany
- These authors contributed equally to this work
| | - Stefan Harmsen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
- These authors contributed equally to this work
| | - Nicolas Beziere
- Institute for Biological and Medical Imaging, Technical University of Munich and Helmholtz Center, Munich, Germany
| | - Hannah Lockau
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - Hsiao-Ting Hsu
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - Ruimin Huang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
- Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, USA
| | - Daniel Razansky
- Institute for Biological and Medical Imaging, Technical University of Munich and Helmholtz Center, Munich, Germany
| | - Vasilis Ntziachristos
- Institute for Biological and Medical Imaging, Technical University of Munich and Helmholtz Center, Munich, Germany
| | - Moritz F. Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
- Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, USA
- Molecular Pharmacology Program, Sloan Kettering Institute, New York, USA
- Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, USA
- Department of Radiology, Weill Cornell Medical College
| |
Collapse
|
66
|
Neuschmelting V, Harmsen S, Beziere N, Lockau H, Hsu HT, Huang R, Razansky D, Ntziachristos V, Kircher MF. Dual-Modality Surface-Enhanced Resonance Raman Scattering and Multispectral Optoacoustic Tomography Nanoparticle Approach for Brain Tumor Delineation. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2018; 14:e1800740. [PMID: 29726109 DOI: 10.1002/smll.v14.23] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Revised: 03/22/2018] [Indexed: 05/23/2023]
Abstract
Difficulty in visualizing glioma margins intraoperatively remains a major issue in the achievement of gross total tumor resection and, thus, better clinical outcome of glioblastoma (GBM) patients. Here, the potential of a new combined optical + optoacoustic imaging method for intraoperative brain tumor delineation is investigated. A strategy using a newly developed gold nanostar synthesis method, Raman reporter chemistry, and silication method to produce dual-modality contrast agents for combined surface-enhanced resonance Raman scattering (SERRS) and multispectral optoacoustic tomography (MSOT) imaging is devised. Following intravenous injection of the SERRS-MSOT-nanostars in brain tumor bearing mice, sequential MSOT imaging is performed in vivo and followed by Raman imaging. MSOT is able to accurately depict GBMs three-dimensionally with high specificity. The MSOT signal is found to correlate well with the SERRS images. Because SERRS enables uniquely sensitive high-resolution surface detection, it could represent an ideal complementary imaging modality to MSOT, which enables real-time, deep tissue imaging in 3D. This dual-modality SERRS-MSOT-nanostar contrast agent reported here is shown to enable high precision depiction of the extent of infiltrating GBMs by Raman- and MSOT imaging in a clinically relevant murine GBM model and could pave new ways for improved image-guided resection of brain tumors.
Collapse
Affiliation(s)
- Volker Neuschmelting
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- Department of Neurosurgery, University Hospital Cologne, Cologne, 50937, Germany
- Institute for Biological and Medical Imaging, Technical University of Neuherberg and Helmholtz Center, Neuherberg, 85764, Germany
| | - Stefan Harmsen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Nicolas Beziere
- Institute for Biological and Medical Imaging, Technical University of Neuherberg and Helmholtz Center, Neuherberg, 85764, Germany
| | - Hannah Lockau
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Hsiao-Ting Hsu
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Ruimin Huang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Daniel Razansky
- Institute for Biological and Medical Imaging, Technical University of Neuherberg and Helmholtz Center, Neuherberg, 85764, Germany
| | - Vasilis Ntziachristos
- Institute for Biological and Medical Imaging, Technical University of Neuherberg and Helmholtz Center, Neuherberg, 85764, Germany
| | - Moritz F Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY, 10065, USA
- Department of Radiology, Weill Cornell Medical College, New York, NY, 10065, USA
| |
Collapse
|
67
|
Detection of Intracellular Gold Nanoparticles: An Overview. MATERIALS 2018; 11:ma11060882. [PMID: 29795017 PMCID: PMC6025619 DOI: 10.3390/ma11060882] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Revised: 05/14/2018] [Accepted: 05/21/2018] [Indexed: 01/10/2023]
Abstract
Photothermal therapy (PTT) takes advantage of unique properties of gold nanoparticles (AuNPs) (nanospheres, nanoshells (AuNSs), nanorods (AuNRs)) to destroy cancer cells or tumor tissues. This is made possible thanks principally to both to the so-called near-infrared biological transparency window, characterized by wavelengths falling in the range 700–1100 nm, where light has its maximum depth of penetration in tissue, and to the efficiency of cellular uptake mechanisms of AuNPs. Consequently, the possible identification of intracellular AuNPs plays a key role for estimating the effectiveness of PTT treatments. Here, we review the recognized detection techniques of such intracellular probes with a special emphasis to the exploitation of near-infrared biological transparency window.
Collapse
|
68
|
Ganipineni LP, Danhier F, Préat V. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. J Control Release 2018; 281:42-57. [PMID: 29753958 DOI: 10.1016/j.jconrel.2018.05.008] [Citation(s) in RCA: 128] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 05/07/2018] [Accepted: 05/09/2018] [Indexed: 12/20/2022]
Abstract
Glioblastoma (GBM) is one of the most aggressive and deadliest central nervous system tumors, and the current standard treatment is surgery followed by radiotherapy with concurrent chemotherapy. Nevertheless, the survival period is notably low. Although ample research has been performed to develop an effective therapeutic strategy for treating GBM, the success of extending patients' survival period and quality of life is limited. This review focuses on the strategies developed to address the challenges associated with drug delivery in GBM, particularly nanomedicine. The first part describes major obstacles to the development of effective GBM treatment strategies. The second part focuses on the conventional chemotherapeutic nanomedicine strategies, their limitations and the novel and advanced strategies of nanomedicine, which could be promising for GBM treatment. We also highlighted the prominence of nanomedicine clinical translation. The near future looks bright following the beginning of clinical translation of nanochemotherapy for GBM.
Collapse
Affiliation(s)
- Lakshmi Pallavi Ganipineni
- Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier, 73 bte B1 73.12, 1200 Brussels, Belgium
| | - Fabienne Danhier
- Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier, 73 bte B1 73.12, 1200 Brussels, Belgium
| | - Véronique Préat
- Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier, 73 bte B1 73.12, 1200 Brussels, Belgium.
| |
Collapse
|
69
|
Meola A, Rao J, Chaudhary N, Sharma M, Chang SD. Gold Nanoparticles for Brain Tumor Imaging: A Systematic Review. Front Neurol 2018; 9:328. [PMID: 29867737 PMCID: PMC5960696 DOI: 10.3389/fneur.2018.00328] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Accepted: 04/25/2018] [Indexed: 11/13/2022] Open
Abstract
Background Demarcation of malignant brain tumor boundaries is critical to achieve complete resection and to improve patient survival. Contrast-enhanced brain magnetic resonance imaging (MRI) is the gold standard for diagnosis and pre-surgical planning, despite limitations of gadolinium (Gd)-based contrast agents to depict tumor margins. Recently, solid metal-based nanoparticles (NPs) have shown potential as diagnostic probes for brain tumors. Gold nanoparticles (GNPs) emerged among those, because of their unique physical and chemical properties and biocompatibility. The aim of the present study is to review the application of GNPs for in vitro and in vivo brain tumor diagnosis. Methods We performed a PubMed search of reports exploring the application of GNPs in the diagnosis of brain tumors in biological models including cells, animals, primates, and humans. The search words were "gold" AND "NP" AND "brain tumor." Two reviewers performed eligibility assessment independently in an unblinded standardized manner. The following data were extracted from each paper: first author, year of publication, animal/cellular model, GNP geometry, GNP size, GNP coating [i.e., polyethylene glycol (PEG) and Gd], blood-brain barrier (BBB) crossing aids, imaging modalities, and therapeutic agents conjugated to the GNPs. Results The PubMed search provided 100 items. A total of 16 studies, published between the 2011 and 2017, were included in our review. No studies on humans were found. Thirteen studies were conducted in vivo on rodent models. The most common shape was a nanosphere (12 studies). The size of GNPs ranged between 20 and 120 nm. In eight studies, the GNPs were covered in PEG. The BBB penetration was increased by surface molecules (nine studies) or by means of external energy sources (in two studies). The most commonly used imaging modalities were MRI (four studies), surface-enhanced Raman scattering (three studies), and fluorescent microscopy (three studies). In two studies, the GNPs were conjugated with therapeutic agents. Conclusion Experimental studies demonstrated that GNPs might be versatile, persistent, and safe contrast agents for multimodality imaging, thus enhancing the tumor edges pre-, intra-, and post-operatively improving microscopic precision. The diagnostic GNPs might also be used for multiple therapeutic approaches, namely as "theranostic" NPs.
Collapse
Affiliation(s)
- Antonio Meola
- Department of Neurosurgery, Stanford University, Stanford, CA, United States
| | - Jianghong Rao
- Department of Radiology, Stanford University, Stanford, CA, United States
| | - Navjot Chaudhary
- Department of Neurosurgery, Stanford University, Stanford, CA, United States
| | - Mayur Sharma
- Department of Neurosurgery, University of Louisville, Louisville, KY, United States
| | - Steven D Chang
- Department of Neurosurgery, Stanford University, Stanford, CA, United States
| |
Collapse
|
70
|
Huang LC, Chang YC, Wu YS, Sun WL, Liu CC, Sze CI, Chen SY. Glioblastoma cells labeled by robust Raman tags for enhancing imaging contrast. BIOMEDICAL OPTICS EXPRESS 2018; 9:2142-2153. [PMID: 29760976 PMCID: PMC5946777 DOI: 10.1364/boe.9.002142] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 03/27/2018] [Accepted: 03/29/2018] [Indexed: 05/16/2023]
Abstract
Complete removal of a glioblastoma multiforme (GBM), a highly malignant brain tumor, is challenging due to its infiltrative characteristics. Therefore, utilizing imaging agents such as fluorophores to increase the contrast between GBM and normal cells can help neurosurgeons to locate residual cancer cells during image guided surgery. In this work, Raman tag based labeling and imaging for GBM cells in vitro is described and evaluated. The cell membrane of a GBM adsorbs a substantial amount of functionalized Raman tags through overexpression of the epidermal growth factor receptor (EGFR) and "broadcasts" stronger pre-defined Raman signals than normal cells. The average ratio between Raman signals from a GBM cell and autofluorescence from a normal cell can be up to 15. In addition, the intensity of these images is stable under laser illuminations without suffering from the severe photo-bleaching that usually occurs in fluorescent imaging. Our results show that labeling and imaging GBM cells via robust Raman tags is a viable alternative method to distinguish them from normal cells. This Raman tag based method can be used solely or integrated into an existing fluorescence system to improve the identification of infiltrative glial tumor cells around the boundary, which will further reduce GBM recurrence. In addition, it can also be applied/extended to other types of cancer to improve the effectiveness of image guided surgery.
Collapse
Affiliation(s)
- Li-Ching Huang
- Department of Photonics, National Cheng Kung University, Tainan, 70101, Taiwan
| | - Yung-Ching Chang
- Department of Photonics, National Cheng Kung University, Tainan, 70101, Taiwan
| | - Yi-Syuan Wu
- Departmet of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan
| | - Wei-Lun Sun
- Department of Photonics, National Cheng Kung University, Tainan, 70101, Taiwan
| | - Chan-Chuan Liu
- Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan
| | - Chun-I Sze
- Departmet of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan
| | - Shiuan-Yeh Chen
- Department of Photonics, National Cheng Kung University, Tainan, 70101, Taiwan
- Advanced Optoelectronic Technology Center, National Cheng Kung University, Tainan, 70101, Taiwan
| |
Collapse
|
71
|
Li Y, Wei Q, Ma F, Li X, Liu F, Zhou M. Surface-enhanced Raman nanoparticles for tumor theranostics applications. Acta Pharm Sin B 2018; 8:349-359. [PMID: 29881674 PMCID: PMC5989827 DOI: 10.1016/j.apsb.2018.03.007] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2018] [Revised: 03/07/2018] [Accepted: 03/14/2018] [Indexed: 02/07/2023] Open
Abstract
Raman spectroscopy, amplified by surface-enhanced Raman scattering (SERS) nanoparticles, can provide an in vivo imaging modality due to its high molecular specificity, high sensitivity, and negligible autofluorescence. The basis, composition, and methodologies developed for SERS nanoparticles are herein described. The research hotspots that are the focus in this paper are tumor imaging-guided theranostics and biosensing. The next breakthrough may be the development of biocompatible SERS nanoparticles and spectroscopic devices for clinical applications.
Collapse
Affiliation(s)
- Yangyang Li
- Department of Nuclear Medicine & Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China
- Institute of Translational Medicine, Zhejiang University, Hangzhou 310009, China
| | - Qiaolin Wei
- Department of Nuclear Medicine & Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China
- Institute of Translational Medicine, Zhejiang University, Hangzhou 310009, China
| | - Fei Ma
- Department of Nuclear Medicine & Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China
- Institute of Translational Medicine, Zhejiang University, Hangzhou 310009, China
| | - Xin Li
- Department of Interventional Radiology, Chinese PLA General Hospital, Beijing 100853, China
| | - Fengyong Liu
- Department of Interventional Radiology, Chinese PLA General Hospital, Beijing 100853, China
| | - Min Zhou
- Department of Nuclear Medicine & Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China
- Institute of Translational Medicine, Zhejiang University, Hangzhou 310009, China
- State Key Laboratory of Modern Optical Instrumentations, Zhejiang University, Hangzhou 310058, China
| |
Collapse
|
72
|
Andrlová H, Mastroianni J, Madl J, Kern JS, Melchinger W, Dierbach H, Wernet F, Follo M, Technau-Hafsi K, Has C, Rao Mittapalli V, Idzko M, Herr R, Brummer T, Ungefroren H, Busch H, Boerries M, Narr A, Ihorst G, Vennin C, Schmitt-Graeff A, Minguet S, Timpson P, Duyster J, Meiss F, Römer W, Zeiser R. Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression. Oncotarget 2018; 8:42901-42916. [PMID: 28476030 PMCID: PMC5522114 DOI: 10.18632/oncotarget.17160] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Accepted: 03/14/2017] [Indexed: 02/04/2023] Open
Abstract
Novel targeted and immunotherapeutic approaches have revolutionized the treatment of metastatic melanoma. A better understanding of the melanoma-microenvironment, in particular the interaction of cells with extracellular matrix molecules, may help to further improve these new therapeutic strategies.We observed that the extracellular matrix molecule biglycan (Bgn) was expressed in certain human melanoma cells and primary fibroblasts when evaluated by microarray-based gene expression analysis. Bgn expression in the melanoma tissues correlated with low overall-survival and low progression-free-survival in patients. To understand the functional role of Bgn we used gene-targeted mice lacking functional Bgn. Here we observed that melanoma growth, metastasis-formation and tumor-related death were reduced in Bgn-/- mice compared to Bgn+/+ mice. In vitro invasion of melanoma cells into organotypic-matrices derived from Bgn-/- fibroblasts was reduced compared to melanoma invasion into Bgn-proficient matrices. Tissue stiffness as determined by atomic-force-microscopy was reduced in Bgn-/- matrices. Isolation of melanoma cells and fibroblasts from the stiffer Bgn+/+ matrices revealed an increase in integrin-β1 expression compared to the Bgn-/- fibroblast matrices. Overexpression of integrin-β1 in B16-melanoma cells abolished the survival benefit seen in Bgn-/- mice. Consistent with the studies performed in mice, the abundance of Bgn-expression in human melanoma samples positively correlated with the expression of integrin-β1, which is in agreement with results from the organotypic invasion-assay and the in vivo mouse studies.This study describes a novel role for Bgn-related tissue stiffness in the melanoma-microenvironment via regulation of integrin-β1 expression by melanoma cells in both mice and humans.
Collapse
Affiliation(s)
- Hana Andrlová
- Department of Hematology and Oncology, University Medical Center, Faculty of Medicine, Freiburg, Germany
| | - Justin Mastroianni
- Department of Hematology and Oncology, University Medical Center, Faculty of Medicine, Freiburg, Germany
| | - Josef Madl
- Faculty of Biology, Albert Ludwigs University, Freiburg, Germany.,BIOSS Centre for Biological Signalling Studies, Albert Ludwigs University Freiburg, Freiburg, Germany
| | - Johannes S Kern
- Department of Dermatology and Venereology, University Medical Center, Freiburg, Germany
| | - Wolfgang Melchinger
- Department of Hematology and Oncology, University Medical Center, Faculty of Medicine, Freiburg, Germany
| | - Heide Dierbach
- Department of Hematology and Oncology, University Medical Center, Faculty of Medicine, Freiburg, Germany
| | - Florian Wernet
- Department of Hematology and Oncology, University Medical Center, Faculty of Medicine, Freiburg, Germany
| | - Marie Follo
- Department of Hematology and Oncology, University Medical Center, Faculty of Medicine, Freiburg, Germany
| | - Kristin Technau-Hafsi
- Department of Dermatology and Venereology, University Medical Center, Freiburg, Germany
| | - Cristina Has
- Department of Dermatology and Venereology, University Medical Center, Freiburg, Germany
| | | | - Marco Idzko
- Department of Pneumology, University Medical Center, Freiburg, Germany
| | - Ricarda Herr
- Institut für Molekulare Medizin und Zellforschung, University Medical Center, Freiburg, Germany
| | - Tilman Brummer
- Institut für Molekulare Medizin und Zellforschung, University Medical Center, Freiburg, Germany
| | | | - Hauke Busch
- First Department of Medicine, University of Lübeck, Lübeck, Germany.,German Cancer Consortium (DKTK), Freiburg, Germany.,Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Melanie Boerries
- Institut für Molekulare Medizin und Zellforschung, University Medical Center, Freiburg, Germany.,German Cancer Consortium (DKTK), Freiburg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Andreas Narr
- Department of Immunology, BIOSS Center for Biological Signaling Studies, Faculty of Biology, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.,Center of Chronic Immunodeficiency CCI, University Clinics and Medical Faculty, Freiburg, Germany
| | - Gabriele Ihorst
- Clinical Trials Unit, University Medical Center, Freiburg, Germany
| | - Claire Vennin
- The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, Australia
| | - Annette Schmitt-Graeff
- Department of Pathology, University Medical Center, Faculty of Medicine, Freiburg, Germany
| | - Susana Minguet
- Department of Immunology, BIOSS Center for Biological Signaling Studies, Faculty of Biology, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.,Center of Chronic Immunodeficiency CCI, University Clinics and Medical Faculty, Freiburg, Germany
| | - Paul Timpson
- The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, Australia
| | - Justus Duyster
- Department of Hematology and Oncology, University Medical Center, Faculty of Medicine, Freiburg, Germany
| | - Frank Meiss
- Department of Dermatology and Venereology, University Medical Center, Freiburg, Germany
| | - Winfried Römer
- Faculty of Biology, Albert Ludwigs University, Freiburg, Germany.,BIOSS Centre for Biological Signalling Studies, Albert Ludwigs University Freiburg, Freiburg, Germany
| | - Robert Zeiser
- Department of Hematology and Oncology, University Medical Center, Faculty of Medicine, Freiburg, Germany.,BIOSS Centre for Biological Signalling Studies, Albert Ludwigs University Freiburg, Freiburg, Germany
| |
Collapse
|
73
|
Nagy-Simon T, Potara M, Craciun AM, Licarete E, Astilean S. IR780-dye loaded gold nanoparticles as new near infrared activatable nanotheranostic agents for simultaneous photodynamic and photothermal therapy and intracellular tracking by surface enhanced resonant Raman scattering imaging. J Colloid Interface Sci 2018; 517:239-250. [PMID: 29428811 DOI: 10.1016/j.jcis.2018.02.007] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2017] [Revised: 02/02/2018] [Accepted: 02/02/2018] [Indexed: 01/01/2023]
Abstract
Due to the good transparency of the human tissue in the biological spectral window, near-infrared (NIR)-dye loaded nanosystems enable more effective light-activated therapy and better contrast imaging with major impact on nanomedicine. Herein, we prepare Pluronic coated gold nanoparticles incorporating the hydrophobic NIR dye, IR780 iodide (GNP-Plu-IR780) to provide water-solubility and stability and demonstrate the proficiency of combining photodynamic and photothermal therapeutic activity with surface-enhanced resonance Raman scattering (SERRS) imaging facility. The potential of GNP-Plu-IR780 to operate as NIR-activatable agents was first assessed in aqueous solution by singlet oxygen generation measurements and monitoring the temperature increase of the nanoparticles. Subsequent in vitro uptake studies by dark field and differential interference contrast (DIC) microscopy reveal massive internalization of GNP-Plu-IR780 by murine colon carcinoma cells (C-26). Moreover, by exploiting the SERRS effect under 785 nm laser excitation we were able to perform intracellular tracking of GNP-Plu-IR780. Finally, NIR irradiation experiments conducted in vitro against C-26 cells show efficient phototherapeutic activity induced by GNP-Plu-IR780 with no dark cytotoxicity. Moreover, when compared to the administration of free drug or non-loaded GNP-Plu, the higher phototherapeutic activity of GNP-Plu-IR780 indicates the occurrence of cooperative synergistic effects by simultaneous photodynamic and photothermal activity.
Collapse
Affiliation(s)
- T Nagy-Simon
- Nanobiophotonics and Laser Microspectroscopy Center, Interdisciplinary Research Institute in Bio-Nano-Sciences, Babes-Bolyai University, T Laurian 42, 400271 Cluj-Napoca, Romania
| | - M Potara
- Nanobiophotonics and Laser Microspectroscopy Center, Interdisciplinary Research Institute in Bio-Nano-Sciences, Babes-Bolyai University, T Laurian 42, 400271 Cluj-Napoca, Romania
| | - A-M Craciun
- Nanobiophotonics and Laser Microspectroscopy Center, Interdisciplinary Research Institute in Bio-Nano-Sciences, Babes-Bolyai University, T Laurian 42, 400271 Cluj-Napoca, Romania
| | - E Licarete
- Molecular Biology Center, Interdisciplinary Research Institute in Bio-Nano-Sciences and Faculty of Biology, Babes-Bolyai University, M Kogalniceanu 1, 400084 Cluj-Napoca, Romania
| | - S Astilean
- Nanobiophotonics and Laser Microspectroscopy Center, Interdisciplinary Research Institute in Bio-Nano-Sciences, Babes-Bolyai University, T Laurian 42, 400271 Cluj-Napoca, Romania; Faculty of Physics, Babes-Bolyai University, M Kogalniceanu 1, 400084 Cluj-Napoca, Romania.
| |
Collapse
|
74
|
|
75
|
Duro-Castano A, Gallon E, Decker C, Vicent MJ. Modulating angiogenesis with integrin-targeted nanomedicines. Adv Drug Deliv Rev 2017; 119:101-119. [PMID: 28502767 DOI: 10.1016/j.addr.2017.05.008] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2017] [Revised: 04/12/2017] [Accepted: 05/09/2017] [Indexed: 12/20/2022]
Abstract
Targeting angiogenesis-related pathologies, which include tumorigenesis and metastatic processes, has become an attractive strategy for the development of efficient guided nanomedicines. In this respect, integrins are cell-adhesion molecules involved in angiogenesis signaling pathways and are overexpressed in many angiogenic processes. Therefore, they represent specific biomarkers not only to monitor disease progression but also to rationally design targeted nanomedicines. Arginine-glycine-aspartic (RGD) containing peptides that bind to specific integrins have been widely utilized to provide ligand-mediated targeting capabilities to small molecules, peptides, proteins, and antibodies, as well as to drug/imaging agent-containing nanomedicines, with the final aim of maximizing their therapeutic index. Within this review, we aim to cover recent and relevant examples of different integrin-assisted nanosystems including polymeric nanoconstructs, liposomes, and inorganic nanoparticles applied in drug/gene therapy as well as imaging and theranostics. We will also critically address the overall benefits of integrin-targeting.
Collapse
Affiliation(s)
- Aroa Duro-Castano
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab., Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| | - Elena Gallon
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab., Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| | - Caitlin Decker
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab., Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| | - María J Vicent
- Centro de Investigación Príncipe Felipe, Polymer Therapeutics Lab., Av. Eduardo Primo Yúfera 3, E-46012 Valencia, Spain.
| |
Collapse
|
76
|
Pal S, Harmsen S, Oseledchyk A, Hsu HT, Kircher MF. MUC1 Aptamer Targeted SERS Nanoprobes. ADVANCED FUNCTIONAL MATERIALS 2017; 27:1606632. [PMID: 29147108 PMCID: PMC5685177 DOI: 10.1002/adfm.201606632] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Recently, surface-enhanced Raman scattering (SERS) nanoprobes (NPs) have shown promise in the field of cancer imaging due to their unparalleled signal specificity and high sensitivity. Here we report the development of a DNA aptamer targeted SERS NP. Recently, aptamers are being investigated as a viable alternative to more traditional antibody targeting due to their low immunogenicity and low cost of production. We developed a strategy to functionalize SERS NPs with DNA aptamers, which target Mucin1 (MUC1) in human breast cancer (BC). Thorough in vitro characterization studies demonstrated excellent serum stability and specific binding of the targeted NPs to MUC1. In order to test their in vivo targeting capability, we co-injected MUC1-targeted SERS NPs, and as controls non-targeted and blocked MUC1-targeted SERS NPs in BC xenograft mouse models. A two-tumor mouse model with differential expression of MUC1 (MDA-MB-468 and MDA-MB-453) was used to control for active versus passive targeting in the same animals. The results showed that the targeted SERS NPs home to the tumors via active targeting of MUC1, with low levels of passive targeting. We expect this strategy to be an advantageous alternative to antibody-based targeting and useful for targeted imaging of tumor extent, progression, and therapeutic response.
Collapse
Affiliation(s)
- Suchetan Pal
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Stefan Harmsen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Anton Oseledchyk
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Hsiao-Ting Hsu
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Moritz F. Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, Cornell University, New York, NY 10065, USA
| |
Collapse
|
77
|
Pal S, Harmsen S, Oseledchyk A, Hsu HT, Kircher MF. MUC1 Aptamer Targeted SERS Nanoprobes. ADVANCED FUNCTIONAL MATERIALS 2017; 27. [PMID: 29147108 DOI: 10.1002/adfm.v27.32] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
Recently, surface-enhanced Raman scattering (SERS) nanoprobes (NPs) have shown promise in the field of cancer imaging due to their unparalleled signal specificity and high sensitivity. Here we report the development of a DNA aptamer targeted SERS NP. Recently, aptamers are being investigated as a viable alternative to more traditional antibody targeting due to their low immunogenicity and low cost of production. We developed a strategy to functionalize SERS NPs with DNA aptamers, which target Mucin1 (MUC1) in human breast cancer (BC). Thorough in vitro characterization studies demonstrated excellent serum stability and specific binding of the targeted NPs to MUC1. In order to test their in vivo targeting capability, we co-injected MUC1-targeted SERS NPs, and as controls non-targeted and blocked MUC1-targeted SERS NPs in BC xenograft mouse models. A two-tumor mouse model with differential expression of MUC1 (MDA-MB-468 and MDA-MB-453) was used to control for active versus passive targeting in the same animals. The results showed that the targeted SERS NPs home to the tumors via active targeting of MUC1, with low levels of passive targeting. We expect this strategy to be an advantageous alternative to antibody-based targeting and useful for targeted imaging of tumor extent, progression, and therapeutic response.
Collapse
Affiliation(s)
- Suchetan Pal
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Stefan Harmsen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Anton Oseledchyk
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Hsiao-Ting Hsu
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Moritz F Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, Cornell University, New York, NY 10065, USA
| |
Collapse
|
78
|
Wang YW, Reder NP, Kang S, Glaser AK, Liu JTC. Multiplexed Optical Imaging of Tumor-Directed Nanoparticles: A Review of Imaging Systems and Approaches. Nanotheranostics 2017; 1:369-388. [PMID: 29071200 PMCID: PMC5647764 DOI: 10.7150/ntno.21136] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Accepted: 07/08/2017] [Indexed: 12/18/2022] Open
Abstract
In recent decades, various classes of nanoparticles have been developed for optical imaging of cancers. Many of these nanoparticles are designed to specifically target tumor sites, and specific cancer biomarkers, to facilitate the visualization of tumors. However, one challenge for accurate detection of tumors is that the molecular profiles of most cancers vary greatly between patients as well as spatially and temporally within a single tumor mass. To overcome this challenge, certain nanoparticles and imaging systems have been developed to enable multiplexed imaging of large panels of cancer biomarkers. Multiplexed molecular imaging can potentially enable sensitive tumor detection, precise delineation of tumors during interventional procedures, and the prediction/monitoring of therapy response. In this review, we summarize recent advances in systems that have been developed for the imaging of optical nanoparticles that can be heavily multiplexed, which include surface-enhanced Raman-scattering nanoparticles (SERS NPs) and quantum dots (QDs). In addition to surveying the optical properties of these various types of nanoparticles, and the most-popular multiplexed imaging approaches that have been employed, representative preclinical and clinical imaging studies are also highlighted.
Collapse
Affiliation(s)
- Yu Winston Wang
- Department of Mechanical Engineering, University of Washington, Seattle, WA 98195, USA
| | - Nicholas P Reder
- Department of Mechanical Engineering, University of Washington, Seattle, WA 98195, USA.,Department of Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA
| | - Soyoung Kang
- Department of Mechanical Engineering, University of Washington, Seattle, WA 98195, USA
| | - Adam K Glaser
- Department of Mechanical Engineering, University of Washington, Seattle, WA 98195, USA
| | - Jonathan T C Liu
- Department of Mechanical Engineering, University of Washington, Seattle, WA 98195, USA
| |
Collapse
|
79
|
Wall MA, Shaffer TM, Harmsen S, Tschaharganeh DF, Huang CH, Lowe SW, Drain CM, Kircher MF. Chelator-Free Radiolabeling of SERRS Nanoparticles for Whole-Body PET and Intraoperative Raman Imaging. Am J Cancer Res 2017; 7:3068-3077. [PMID: 28839464 PMCID: PMC5566106 DOI: 10.7150/thno.18019] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2016] [Accepted: 05/17/2017] [Indexed: 12/21/2022] Open
Abstract
A single contrast agent that offers whole-body non-invasive imaging along with the superior sensitivity and spatial resolution of surface-enhanced resonance Raman scattering (SERRS) imaging would allow both pre-operative mapping and intraoperative imaging and thus be highly desirable. We hypothesized that labeling our recently reported ultrabright SERRS nanoparticles with a suitable radiotracer would enable pre-operative identification of regions of interest with whole body imaging that can be rapidly corroborated with a Raman imaging device or handheld Raman scanner in order to provide high precision guidance during surgical procedures. Here we present a straightforward new method that produces radiolabeled SERRS nanoparticles for combined positron emission tomography (PET)-SERRS tumor imaging without requiring the attachment of molecular chelators. We demonstrate the utility of these PET-SERRS nanoparticles in several proof-of-concept studies including lymph node (LN) tracking, intraoperative guidance for LN resection, and cancer imaging after intravenous injection. We anticipate that the radiolabeling method presented herein can be applied generally to nanoparticle substrates of various materials by first coating them with a silica shell and then applying the chelator-free protocol.
Collapse
|
80
|
Abstract
The unique spectral signatures and biologically inert compositions of surface-enhanced resonance Raman scattering (SERRS) nanoparticles make them promising contrast agents for in vivo cancer imaging. Our SERRS nanoparticles consist of a 60-nm gold nanoparticle core that is encapsulated in a 15-nm-thick silica shell wherein the resonant Raman reporter is embedded. Subtle aspects of their preparation can shift their limit of detection by orders of magnitude. In this protocol, we present the optimized, step-by-step procedure for generating reproducible SERRS nanoparticles with femtomolar (10-15 M) limits of detection. We provide ways of characterizing the optical properties of SERRS nanoparticles using UV/VIS and Raman spectroscopy, and their physicochemical properties using transmission electron microscopy and nanoparticle tracking analysis. We introduce several applications of these nanoprobes for biomedical research, with a focus on intraoperative cancer imaging via Raman imaging. A detailed account is provided for successful i.v. administration of SERRS nanoparticles such that delineation of cancerous lesions can be achieved in vivo and ex vivo on resected tissues without the need for specific biomarker targeting. This straightforward, yet comprehensive, protocol-from initial de novo gold nanoparticle synthesis to SERRS nanoparticle contrast-enhanced preclinical Raman imaging in animal models-takes ∼96 h.
Collapse
|
81
|
Sattiraju A, Xiong X, Pandya DN, Wadas TJ, Xuan A, Sun Y, Jung Y, Sai KKS, Dorsey JF, Li KC, Mintz A. Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3-Targeted Liposomes. Mol Cancer Ther 2017; 16:2191-2200. [PMID: 28619756 DOI: 10.1158/1535-7163.mct-16-0907] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2016] [Revised: 04/26/2017] [Accepted: 06/08/2017] [Indexed: 11/16/2022]
Abstract
Glioblastoma (GBM) is the most common primary malignant astrocytoma characterized by extensive invasion, angiogenesis, hypoxia, and micrometastasis. Despite the relatively leaky nature of GBM blood vessels, effective delivery of antitumor therapeutics has been a major challenge due to the complications caused by the blood-brain barrier (BBB) and the highly torturous nature of newly formed tumor vasculature (blood tumor barrier-BTB). External beam radiotherapy was previously shown to be an effective means of permeabilizing central nervous system (CNS) barriers. By using targeted short-ranged radionuclides, we show for the first time that our targeted actinium-225-labeled αvβ3-specific liposomes (225Ac-IA-TLs) caused catastrophic double stranded DNA breaks and significantly enhanced the permeability of BBB and BTB in mice bearing orthotopic GBMs. Histologic studies revealed characteristic α-particle induced double strand breaks within tumors but was not significantly present in normal brain regions away from the tumor where BBB permeability was observed. These findings indicate that the enhanced vascular permeability in these distal regions did not result from direct α-particle-induced DNA damage. On the basis of these results, in addition to their direct antitumor effects, 225Ac-IA-TLs can potentially be used to enhance the permeability of BBB and BTB for effective delivery of systemically administered antitumor therapeutics. Mol Cancer Ther; 16(10); 2191-200. ©2017 AACR.
Collapse
Affiliation(s)
- Anirudh Sattiraju
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Xiaobing Xiong
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Darpan N Pandya
- Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Thaddeus J Wadas
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina.,Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Ang Xuan
- Department of Nuclear Medicine and Radiology, the People's Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Yao Sun
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Youngkyoo Jung
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | | | - Jay F Dorsey
- Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - King C Li
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina
| | - Akiva Mintz
- Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina. .,Columbia University, New York, New York
| |
Collapse
|
82
|
Abstract
The fields of biomedical nanotechnology and theranostics have enjoyed exponential growth in recent years. The "Molecular Imaging in Nanotechnology and Theranostics" (MINT) Interest Group of the World Molecular Imaging Society (WMIS) was created in order to provide a more organized and focused forum on these topics within the WMIS and at the World Molecular Imaging Conference (WMIC). The interest group was founded in 2015 and was officially inaugurated during the 2016 WMIC. The overarching goal of MINT is to bring together the many scientists who work on molecular imaging approaches using nanotechnology and those that work on theranostic agents. MINT therefore represents scientists, labs, and institutes that are very diverse in their scientific backgrounds and areas of expertise, reflecting the wide array of materials and approaches that drive these fields. In this short review, we attempt to provide a condensed overview over some of the key areas covered by MINT. Given the breadth of the fields and the given space constraints, we have limited the coverage to the realm of nanoconstructs, although theranostics is certainly not limited to this domain. We will also focus only on the most recent developments of the last 3-5 years, in order to provide the reader with an intuition of what is "in the pipeline" and has potential for clinical translation in the near future.
Collapse
Affiliation(s)
- Chrysafis Andreou
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Suchetan Pal
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Lara Rotter
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Jiang Yang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Moritz F Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
- Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
- Department of Radiology, Weill Cornell Medical College, New York, NY, 10065, USA.
| |
Collapse
|
83
|
Gao X, Yue Q, Liu Z, Ke M, Zhou X, Li S, Zhang J, Zhang R, Chen L, Mao Y, Li C. Guiding Brain-Tumor Surgery via Blood-Brain-Barrier-Permeable Gold Nanoprobes with Acid-Triggered MRI/SERRS Signals. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2017; 29:1603917. [PMID: 28295679 DOI: 10.1002/adma.201603917] [Citation(s) in RCA: 117] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/24/2016] [Revised: 02/03/2017] [Indexed: 05/27/2023]
Abstract
Surgical resection is a mainstay in the treatment of malignant brain tumors. Surgeons, however, face great challenges in distinguishing tumor margins due to their infiltrated nature. Here, a pair of gold nanoprobes that enter a brain tumor by crossing the blood-brain barrier is developed. The acidic tumor environment triggers their assembly with the concomitant activation of both magnetic resonance (MR) and surface-enhanced resonance Raman spectroscopy (SERRS) signals. While the bulky aggregates continuously trap into the tumor interstitium, the intact nanoprobes in normal brain tissue can be transported back into the blood stream in a timely manner. Experimental results show that physiological acidity triggers nanoparticle assembly by forming 3D spherical nanoclusters with remarkable MR and SERRS signal enhancements. The nanoprobes not only preoperatively define orthotopic glioblastoma xenografts by magnetic resonance imaging (MRI) with high sensitivity and durability in vivo, but also intraoperatively guide tumor excision with the assistance of a handheld Raman scanner. Microscopy studies verify the precisely demarcated tumor margin marked by the assembled nanoprobes. Taking advantage of the nanoprobes' rapid excretion rate and the extracellular acidification as a hallmark of solid tumors, these nanoprobes are promising in improving brain-tumor surgical outcome with high specificity, safety, and universality.
Collapse
Affiliation(s)
- Xihui Gao
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China
| | - Qi Yue
- Department of Neurosurgery, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China
| | - Zining Liu
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China
| | - Mengjing Ke
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China
| | - Xingyu Zhou
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China
| | - Sihan Li
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China
| | - Jianping Zhang
- Department of Nuclear Medicine, Shanghai Cancer Center, Fudan University, 270 Dongan Road, Shanghai, 200032, China
| | - Ren Zhang
- Center of Analysis and Measurement, Fudan University, 220 Handan Road, Shanghai, 200433, China
| | - Liang Chen
- Department of Neurosurgery, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China
| | - Ying Mao
- Department of Neurosurgery, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China
- State Key Laboratory of Medical Neurobiology, School of Basic Medical Sciences and Institutes of Brain Science, Fudan University, 138 Yixueyuan Road, Shanghai, 200032, China
| | - Cong Li
- Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China
| |
Collapse
|
84
|
Huang J, Liu F, Liu Z, Tang H, Wu H, Gong Q, Chen J. Immune Checkpoint in Glioblastoma: Promising and Challenging. Front Pharmacol 2017; 8:242. [PMID: 28536525 PMCID: PMC5422441 DOI: 10.3389/fphar.2017.00242] [Citation(s) in RCA: 107] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2017] [Accepted: 04/18/2017] [Indexed: 12/18/2022] Open
Abstract
Glioblastoma (GBM) is a severe malignant brain cancer with poor overall survival. Conventional intervention remains dismal to prevent recurrence and deterioration of GBM cell. Recent years have witnessed exciting breakthroughs in novel immune strategies, especially checkpoint inhibitors, some of which have become adjuvant setting after standard of care in melanoma. Several clinical trials of checkpoint inhibitors are ongoing in glioblastoma and other brain carcinomas. Plus, synergistic combinations of checkpoint inhibitors with conventional therapy strategies—radiotherapy, temozolomide, bevacizumab, and corticosteroids are now being exploited and applied in clinical settings. This review highlights the recent developments of checkpoints in GBM immunotherapy to provide a brief and comprehensive review of current treatment options. Furthermore, we will discuss challenges remained, such as unique immune system of central nervous system (CNS), immune-related toxicities, synergies, and adverse interactions of combination therapies.
Collapse
Affiliation(s)
- Jing Huang
- Department of Psychiatry, the Second Xiangya Hospital, Central South UniversityChangsha, China.,Mental Health Institute of the Second Xiangya Hospital, Chinese National Clinical Research Center on Mental Disorders (Xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Central South UniversityChangsha, China
| | - Fangkun Liu
- Department of Neurosurgery, Xiangya Hospital, Central South University (CSU)Changsha, China
| | - Zhixiong Liu
- Department of Neurosurgery, Xiangya Hospital, Central South University (CSU)Changsha, China
| | - Hui Tang
- Department of Psychiatry, the Second Xiangya Hospital, Central South UniversityChangsha, China.,Mental Health Institute of the Second Xiangya Hospital, Chinese National Clinical Research Center on Mental Disorders (Xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Central South UniversityChangsha, China
| | - Haishan Wu
- Department of Psychiatry, the Second Xiangya Hospital, Central South UniversityChangsha, China.,Mental Health Institute of the Second Xiangya Hospital, Chinese National Clinical Research Center on Mental Disorders (Xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Central South UniversityChangsha, China
| | - Qianni Gong
- Department of Minimally Invasive Surgery, the Second Xiangya Hospital, Central South UniversityChangsha, China
| | - Jindong Chen
- Department of Psychiatry, the Second Xiangya Hospital, Central South UniversityChangsha, China.,Mental Health Institute of the Second Xiangya Hospital, Chinese National Clinical Research Center on Mental Disorders (Xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Central South UniversityChangsha, China
| |
Collapse
|
85
|
Yuan Y, Panwar N, Yap SHK, Wu Q, Zeng S, Xu J, Tjin SC, Song J, Qu J, Yong KT. SERS-based ultrasensitive sensing platform: An insight into design and practical applications. Coord Chem Rev 2017. [DOI: 10.1016/j.ccr.2017.02.006] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
86
|
Oseledchyk A, Andreou C, Wall MA, Kircher MF. Folate-Targeted Surface-Enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detection of Microscopic Ovarian Cancer. ACS NANO 2017; 11:1488-1497. [PMID: 27992724 PMCID: PMC5502101 DOI: 10.1021/acsnano.6b06796] [Citation(s) in RCA: 71] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Ovarian cancer has a unique pattern of metastatic spread, in that it initially spreads locally within the peritoneal cavity. This is in contrast to most other cancer types, which metastasize early on via the bloodstream to distant sites. This unique behavior opens up an opportunity for local application of both therapeutic and imaging agents. Upon initial diagnosis, 75% of patients already present with diffuse peritoneal spread involving abdominal organs. Complete resection of all tumor implants has been shown to be a major factor for improved survival. Unfortunately, it is currently not possible for surgeons to visualize microscopic implants, impeding their removal and leading to tumor recurrences and poor outcomes in most patients. Thus, there is a great need for new intraoperative imaging techniques that can overcome this hurdle. We devised a method that employs folate receptor (FR)-targeted surface-enhanced resonance Raman scattering (SERRS) nanoparticles (NPs), as folate receptors are typically overexpressed in ovarian cancer. We report a robust ratiometric imaging approach using anti-FR-SERRS-NPs (αFR-NPs) and nontargeted SERRS-NPs (nt-NPs) multiplexing. We term this method "topically applied surface-enhanced resonance Raman ratiometric spectroscopy" (TAS3RS ("tasers") for short). TAS3RS successfully enabled the detection of tumor lesions in a murine model of human ovarian adenocarcinoma regardless of their size or localization. Tumors as small as 370 μm were detected, as confirmed by bioluminescence imaging and histological staining. TAS3RS holds promise for intraoperative detection of microscopic residual tumors and could reduce recurrence rates in ovarian cancer and other diseases with peritoneal spread.
Collapse
Affiliation(s)
- Anton Oseledchyk
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Chrysafis Andreou
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Matthew A. Wall
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Moritz F. Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA
- Address correspondence to Moritz F. Kircher,
| |
Collapse
|
87
|
Kircher MF. How can we apply the use of surface-enhanced Raman scattering nanoparticles in tumor imaging? Nanomedicine (Lond) 2017; 12:171-174. [DOI: 10.2217/nnm-2016-0385] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Moritz F Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
- Center for Molecular Imaging & Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
- Weill Cornell Medical College of Cornell University, 1300 York Avenue, New York, NY 10065, USA
| |
Collapse
|
88
|
Penthala NR, Janganati V, Alpe TL, Apana SM, Berridge MS, Crooks PA, Borrelli MJ. N-[ 11CH 3]Dimethylaminoparthenolide (DMAPT) uptake into orthotopic 9LSF glioblastoma tumors in the rat. Bioorg Med Chem Lett 2016; 26:5883-5886. [PMID: 27866815 DOI: 10.1016/j.bmcl.2016.11.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2016] [Revised: 11/04/2016] [Accepted: 11/07/2016] [Indexed: 11/27/2022]
Abstract
The aim of this study was to determine the uptake of intravenously administered N-[11CH3]-dimethylaminoparthenolide (DMAPT) into orthotopic 9LSF glioblastoma brain tumors in Fisher 344 rats from positron emission tomography (PET) imaging studies. [11C]methyl iodide (11CH3I) was utilized as a [11C]-labeling reagent to label the precursor methylaminoparthenolide (MAPT) intermediate. From PET imaging studies it was found that brain uptake of N-[11CH3]DMAPT into brain tumor tissue was rapid (30min), and considerably higher than that in the normal brain tissue.
Collapse
Affiliation(s)
- Narsimha Reddy Penthala
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA
| | - Venumadhav Janganati
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA
| | - Terri L Alpe
- College of Medicine, Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA
| | | | | | - Peter A Crooks
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA.
| | - Michael J Borrelli
- Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA; College of Medicine, Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA.
| |
Collapse
|
89
|
Andreou C, Neuschmelting V, Tschaharganeh DF, Huang CH, Oseledchyk A, Iacono P, Karabeber H, Colen RR, Mannelli L, Lowe SW, Kircher MF. Imaging of Liver Tumors Using Surface-Enhanced Raman Scattering Nanoparticles. ACS NANO 2016; 10:5015-26. [PMID: 27078225 PMCID: PMC4884645 DOI: 10.1021/acsnano.5b07200] [Citation(s) in RCA: 102] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Complete surgical resection is the ideal first-line treatment for most liver malignancies. This goal would be facilitated by an intraoperative imaging method that enables more precise visualization of tumor margins and detection of otherwise invisible microscopic lesions. To this end, we synthesized silica-encapsulated surface-enhanced Raman scattering (SERS) nanoparticles (NPs) that act as a molecular imaging agent for liver malignancies. We hypothesized that, after intravenous administration, SERS NPs would avidly home to healthy liver tissue but not to intrahepatic malignancies. We tested these SERS NPs in genetically engineered mouse models of hepatocellular carcinoma and histiocytic sarcoma. After intravenous injection, liver tumors in both models were readily identifiable with Raman imaging. In addition, Raman imaging using SERS NPs enabled detection of microscopic lesions in liver and spleen. We compared the performance of SERS NPs to fluorescence imaging using indocyanine green (ICG). We found that SERS NPs delineate tumors more accurately and are less susceptible to photobleaching. Given the known advantages of SERS imaging, namely, high sensitivity and specific spectroscopic detection, these findings hold promise for improved resection of liver cancer.
Collapse
Affiliation(s)
- Chrysafis Andreou
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New
York, NY 10065, USA
| | - Volker Neuschmelting
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New
York, NY 10065, USA
| | | | - Chun-Hao Huang
- Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer
Center, New York, NY 10065, USA
| | - Anton Oseledchyk
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New
York, NY 10065, USA
| | - Pasquale Iacono
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New
York, NY 10065, USA
| | - Hazem Karabeber
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New
York, NY 10065, USA
| | - Rivka R. Colen
- Department of Radiology, M.D. Anderson Cancer Center, University of
Texas, Houston, Texas, 77030, USA
| | - Lorenzo Mannelli
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New
York, NY 10065, USA
| | - Scott W. Lowe
- Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer
Center, New York, NY 10065, USA
- Howard Hughes Medical Institute, New York, NY 10065, USA
| | - Moritz F. Kircher
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New
York, NY 10065, USA
- Center for Molecular Imaging and Nanotechnology (CMINT), Memorial
Sloan Kettering Cancer Center, New York, NY 10065, USA
- Department of Radiology, Weill Cornell Medical College, New York, NY
10065, USA
| |
Collapse
|